The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice.
 
Amanda Nottke
Employment - Invitae
Stock and Other Ownership Interests - Invitae
Consulting or Advisory Role - Invitae
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); AstraZeneca (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst); ZielBio (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Elise Brimble
Employment - Invitae
Stock and Other Ownership Interests - Invitae
 
Richard L Martin
Employment - Invitae
Stock and Other Ownership Interests - Invitae; LeMaitre Vascular; Moderna Therapeutics; Olink; Pfizer; Tango Therapeutics; Twist Bioscience
Patents, Royalties, Other Intellectual Property - IBM
 
Conner OBrien
Employment - Invitae
Stock and Other Ownership Interests - Invitae
 
Stacie Lindsey
Leadership - Cholangiocarcinoma Foundation
Travel, Accommodations, Expenses - Incyte
 
Melinda Bachini
Honoraria - AstraZeneca; Boehringer Ingelheim; Kinnate Biopharma; Lynx Group; Merck; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lynx Group; Taiho Pharmaceutical
Other Relationship - Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - ECOG-ACRIN; NCCN; NCI
 
Shishir K. Maithel
Consulting or Advisory Role - AstraZeneca
Research Funding - Celgene